Precision radiation therapy yields rare success for liver tumorsOctober 20, 2005Shaped-beam radiation therapy is a promising treatment for life-threatening metastatic liver tumors, according to researchers at the University of Rochester Medical Center who report an 88 percent success rate for controlling the lesions. This is the first evidence that doctors can treat these tumors with radiation, and the results doubled the average length of survival. "Radiation therapy has not been a recommended treatment for liver metastases because of the poor results when whole-liver radiation was used," said Alan Katz, M.D., M.P.H., lead researcher and assistant professor of Radiation Oncology. "High-dose, precision radiation therapy is proving to be a promising therapy for metastatic liver disease and provides an effective treatment option for patients who previously didn't have any." Radiation oncologists at the University's James P. Wilmot Cancer Center are leading the effort to expand shaped-beam radiation therapy - originally designed to treat brain tumors - to target metastatic liver tumors with pinpoint accuracy. Initial treatment results were presented this week at the American Society for Therapeutic Radiology and Oncology's annual meeting in Denver. Many forms of cancer are treated with radiation therapy, but tumors in the liver are difficult to target using conventional techniques because the organ moves during breathing. Shaped-beam radiation therapy, also known as stereotactic body radiation therapy, has expanded treatment options by delivering a high dose of radiation precisely to the tumor, while limiting the damage to healthy tissue surrounding the tumor. In Rochester, doctors treated 72 patients with metastatic liver lesions between April 2001 and October 2004. Most of the patients had colorectal, breast, pancreatic, lung, genitourinary, esophageal and ovarian cancers, which had spread to the liver. The patients had a median of two lesions that ranged from 0.5 centimeters to 12.2 centimeters in diameter. Doctors followed the patients' progress for an average of a year, though some were followed as long as three years, and the average survival was 13 months. "This is remarkable. For people who are facing this deadly disease, doubling the length of survival brings hope to our patients and that is so important," Katz said. Katz led the research, along with Paul Okunieff, M.D., chair of Radiation Oncology, Michael Schell, Ph.D., Christine Huggins, Ph.D., and Madeleine Carey Sampson, M.D. The Wilmot Cancer Center has been leading the research into expanding the use of stereotactic radiation therapy to treat tumors throughout the body. For the past five years, radiation oncologists have been studying its use in treating a variety of primary and metastatic tumors throughout the body and developing models for delivering radiation to organs that cannot be immobilized, such as the lungs and liver. University of Rochester Medical Center |
|||||||||||||||||||||
| Related Radiation Therapy Current Events and Radiation Therapy News Articles Iowa State engineers develop 3-D software to give doctors, students a view inside the body James Oliver picked up an Xbox game controller, looked up to a video screen and used the device's buttons and joystick to fly through a patient's chest cavity for an up-close look at the bottom of the heart. Men leave: Separation and divorce far more common when the wife is the patient A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact. PET imaging response a prognostic factor after thoracic radiation therapy for lung cancer A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. Chemo-radiation before prostate removal may prevent cancer recurrence Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. Radiation therapy technique successfully treats pain in patients with advanced cancer Stereotactic radiosurgery (SRS), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, effectively controls pain in patients with cancer that has spread to the spine. Aiming to avoid damage to neurocognitive areas of the brain during cranial radiation Radiation oncologists at Rush University Medical Center are intent on finding ways to avoid damage to the critically important hippocampus and limbic circuit of the brain when cranial radiation is required to treat existing or potential metastatic cancers. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Preventative brain radiation for lung cancer patients: Benefits and risks A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain. Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone. More Radiation Therapy Current Events and Radiation Therapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||